Back to results
US 5,443,967 AGranted
DNA encoding the cancer associated SCM recognition factor
OwnerBoris Cercek, Lea Cercekinventors
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
OwnerBoris Cercek, Lea Cercekinventors
Estimating the term…
A cancer recognition factor (SCM factor) useful in the performance of the structuredness of the cytoplasmic matrix (SCM) test has been isolated, purified to substantial homogeneity, and characterized, and methods for its use have been described. The factor is a peptide of at least 9 amino acid residues including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to that of the sequence F-L-M-I-D-Q-N-T-K and produces at least a 10 percent decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer. A synthetic SCM factor representing a consensus sequence of M-I-P-P-E-V-K-F-N-K-P-F-V-F-L-M-I-D-Q-N-T-K-V-P-L-F-M-G-K is fully active. Antibodies specific for SCM factor are useful in immunoassays that can detect the factor, including detection in cancer cells grown in vitro. The SCM factor is useful for screening of blood samples and other body fluids or cell aspirates for the presence of malignancy in the donor. The multiple action spectrum of the SCM factor including cancer proliferation and invasion promotion, as well as inhibition of the host's immune defense mechanisms and synthesis of SCM factor by cancer cells, represents a novel target for cancer management. Methods for reducing in vivo activity of the SCM factor, such as dialysis or antibody neutralization, can also be useful in the management of cancer.
A DNA sequence encoding a peptide active in the structuredness of the cytoplasmic matrix (SCM) test, the peptide being a peptide of 22 amino acid residues to 35 amino acid residues with the first two amino-terminal amino acid residues being M-I with no intervening amino acid residue, the peptide encoded by the DNA sequence including a core sequence of 9 amino acid residues having an amphipathicity profile substantially equivalent to the sequence F-L-M-I-D-Q-N-T-K, wherein the sixth amino acid of the core sequence is selected from the group consisting of Q and N, the seventh amino acid of the core sequence is selected from the group consisting of N and Q, and the ninth amino acid of the core sequence is selected from the group consisting of K and R, the peptide producing at least a 10% decrease in the intracellular fluorescence polarization value of lymphocytes capable of responding in the SCM test as isolated from donors afflicted with cancer, in substantial isolation from DNA encoding proteins normally accompanying a peptide active in the SCM test.
A DNA sequence encoding a peptide active in the structuredness of the cytoplasmic matrix (SCM) test and including a core sequence therein, wherein the SCM-active peptide comprises from 13 to 35 amino acid residues and wherein the core sequence comprises 13 amino acid residuals, the core sequence being F-X.sub.13 -F-X.sub.15 -M-X.sub.17 -X.sub.18 -X.sub.19 -X.sub.20 -X.sub.21 -K-X.sub.23 -P, wherein X.sub.13, X.sub.15, X.sub.17, and X.sub.23 are each independently selected from the group consisting of I, L, and V;
A DNA sequence encoding a peptide active in the structuredness of the cytoplasmic matrix (SCM) test and including a core sequence therein, wherein the SCM-active peptide comprises from 18 to 35 amino acids, and wherein the core sequence comprises X.sub.9 -K-P-F-X.sub.13 -F-X.sub.15 -M-X.sub.17 -X.sub.18 -X.sub.19 -X.sub.20 -X.sub.21 -K-X.sub.23 -P-X.sub.25 -F, wherein X.sub.13, X.sub.15, X.sub.17, X.sub.23 and X.sub.25 are each independently selected from the group consisting of I, L, and V;
A DNA sequence encoding a peptide active in the structuredness of the cytoplasmic matrix (SCM) test, the peptide having the amino acid sequence M-X.sub.2 -P-P-X.sub.5 -X.sub.6 -K-F-X.sub.9 -K-P-F-X.sub.13 -F-X.sub.15 -M-X.sub.17 -X.sub.18 -X.sub.19 -X.sub.20 -X.sub.21 -K-X.sub.23 -P-X.sub.25 -F-M-G-K, wherein X.sub.2, X.sub.6, X.sub.13, X.sub.15, X.sub.17, X.sub.23, and X.sub.25 are each independently selected from the group consisting of I, L, and V;
A DNA sequence encoding a peptide active in the structuredness of the cytoplasmic matrix (SCM) test, the peptide having from 29 to 35 amino acid residues, including a core sequence at amino acids 14-22 of F-L-M-I-X.sub.18 -Q-N-T-K, wherein X.sub.18 is selected from the group consisting of D and E, the peptide producing at least a 10% decrease in the intracellular fluorescence polarization value of SCM-responding lymphocytes from donors afflicted with cancer, in substantial isolation from DNA encoding proteins normally accompanying the peptide active in the SCM test.
Dependencies are inferred from the claim text.